---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-25-000071"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:48:14.459623+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas Q1 net loss $76.1M ($0.92/share); cash $221M runway into Q2 2027

## Summary
- Net loss $76.1M ($0.92 per share) vs $62.0M loss in Q1 2024; revenue $4.7M (up from $1.1M).
- R&D expenses fell to $26.6M from $48.8M; restructuring charges $40.9M from reni-cel discontinuation.
- Cash, equivalents, and marketable securities $221.0M; expected to fund operations into Q2 2027.
- Amy Parison appointed CFO; previously SVP Finance and Corporate Controller at Editas since 2022.
- Federal Circuit vacated PTAB decision on CRISPR/Cas9 patents; remanded for further review.

## SEC filing metadata
- accession: 0001650664-25-000071
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000071/0001650664-25-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000071/edit-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-25-000071
- JSON: https://secwatch.observer/filing/0001650664-25-000071.json
- Plain text: https://secwatch.observer/filing/0001650664-25-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.